LeadArt Biotechnologies Completes US$6M Pre-A Financing

LeadArt Biotechnologies, a Boston, MA and Ningbo, China-based biotechnology firm targeted on drug discovery by automating chemoproteomics processes, raised US$6M in Pre-A funding.

The spherical was led by BlueRun Ventures Aster.

The firm intends to make use of the funds to advance the event of its automated chemoproteomics platform and the creation of a human target-probe database.

Led by CEO Feng Ni, LeadArt Biotechnologies is accelerating drug discovery by automating chemoproteomics processes and making a human live-cell target-probe database. Its platform integrates biotechnology and automation applied sciences to find disease-related targets and chemical probes for historically undruggable and unexplored targets.

The firm lately signed a strategic collaboration with AstraZeneca’s iCampus to develop a natural medication preclinical translation platform in Chengdu, China.



Leave a Comment